Sofinnova Partners
Paris-based life-sciences VC; participant in CellCentric's £170m Series D.
Last refreshed: 13 May 2026 · Appears in 1 active topic
Timeline for Sofinnova Partners
CellCentric raises Europe's largest 2026 biotech round
UK Startups and Innovation- What is Sofinnova Partners?
- Sofinnova Partners is a Paris-based life-sciences VC founded in 1972, managing over €2.5bn in AUM across oncology, rare disease, and medical devices investments in Europe and the US.Source: Sofinnova Partners
- Which European VCs backed CellCentric's cancer drug round?
- Sofinnova Partners was among the European investors in CellCentric's £170m Series D, Europe's largest biotech round of 2026, alongside Venrock Healthcare, Pfizer, and Fidelity.Source: Lowdown uk-startups-and-innovation U#4
- Is Sofinnova one of the oldest European biotech VCs?
- Yes. Sofinnova Partners was founded in 1972, making it one of the longest-established dedicated life-sciences venture firms in Europe.Source: Sofinnova Partners
Background
Sofinnova Partners participated in CellCentric's £170m Series D in May 2026 alongside lead Venrock Healthcare Capital Partners, Pfizer, Fidelity, the American Cancer Society BrightEdge vehicle, and others. CellCentric is developing inobrodib, a first-in-class p300/CBP inhibitor for relapsed multiple myeloma and prostate cancer.
Sofinnova Partners is a Paris-based life-sciences venture capital firm founded in 1972, one of the oldest dedicated biotech investors in Europe. It manages over €2.5bn in AUM across multiple funds and backs companies from early-stage through clinical proof-of-concept, with a transatlantic investment mandate spanning Europe and the US. Its portfolio includes oncology, rare disease, infectious disease, and medical devices companies. Sofinnova has offices in Paris, London, and San Francisco.